{"filing":{"accession_number":"0001193125-26-245203","cik":"0000818686","ticker":"TEVJF","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"d342755d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526245203/d342755d8k.htm"},"events":[{"id":8432,"run_id":7398,"accession_number":"0001193125-26-245203","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the results of Teva's Annual Meeting held on May 28, 2026, including shareholder votes on three matters: (1) election of Dr. Sol J. Barer to the Board, (2) advisory approval of named executive officer compensation, and (3) appointment of Kesselman \u0026 Kesselman as independent auditor. The tabulated voting results with For/Against/Abstain/Broker non-votes are the core disclosure, making this a clear shareholder_vote_results event that is material to investors assessing board composition and governance.","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2318,"accession_number":"0001193125-26-245203","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Teva's Annual Meeting held on May 28, 2026, including shareholder votes on three matters: (1) election of Dr. Sol J. Barer to the Board, (2) advisory approval of named executive officer compensation, and (3) appointment of Kesselman \u0026 Kesselman as independent auditor. The tabulated voting results with For/Against/Abstain/Broker non-votes are the core disclosure, making this a clear shareholder_vote_results event that is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:38:19.397868+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2318,"accession_number":"0001193125-26-245203","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Teva's Annual Meeting held on May 28, 2026, including shareholder votes on three matters: (1) election of Dr. Sol J. Barer to the Board, (2) advisory approval of named executive officer compensation, and (3) appointment of Kesselman \u0026 Kesselman as independent auditor. The tabulated voting results with For/Against/Abstain/Broker non-votes are the core disclosure, making this a clear shareholder_vote_results event that is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:38:19.397868+00:00","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-05-28"}]}